Phase 1 trial of oral ASTX727 plus talazoparib in previously treated triple-negative metastatic breast cancer patients.
New Drug Combo Stops Breast Cancer Growth
This Phase 1 study enrolled 34 evaluable patients with previously treated triple-negative, hormone-resistant, or HER2-negative metastatic br…
This new combination may help some patients keep their cancer stable for months when other options have run out.
Talazoparib plus enzalutamide shows high probability of benefit in Japanese mCRPC subgroup
New Math Brings Hope to Japanese Men With Advanced Prostate Cancer
A Bayesian reanalysis of phase III trial data in 116 Japanese patients with metastatic castration-resistant prostate cancer found a 98% prob…
New math suggests a two-drug combo likely works for Japanese men with advanced prostate cancer, even when original trial numbers looked unce…
Talazoparib monotherapy in neoadjuvant triple-negative breast cancer reveals BRN2-driven resistance mechanisms.
Why Some BRCA Breast Cancers Shrug Off Talazoparib Before Surgery
This Phase II neoadjuvant trial evaluated talazoparib in patients with germline mutant breast tumors. Mechanistic analysis showed that BRN2 …
Some BRCA breast cancers shrink under talazoparib, but others find hidden escape routes that let them ignore the drug before surgery.